MX2021006270A - Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa. - Google Patents

Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.

Info

Publication number
MX2021006270A
MX2021006270A MX2021006270A MX2021006270A MX2021006270A MX 2021006270 A MX2021006270 A MX 2021006270A MX 2021006270 A MX2021006270 A MX 2021006270A MX 2021006270 A MX2021006270 A MX 2021006270A MX 2021006270 A MX2021006270 A MX 2021006270A
Authority
MX
Mexico
Prior art keywords
cbd
treatment
tsc
present
cannabidiol
Prior art date
Application number
MX2021006270A
Other languages
English (en)
Inventor
Benjamin Whalley
Claire Williams
William Hind
Royston Gray
Michael Bazelot
Silva Serra Ines De
Andrew Tee
Original Assignee
Gw Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Res Ltd filed Critical Gw Res Ltd
Publication of MX2021006270A publication Critical patent/MX2021006270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se relaciona con el uso de cannabidiol (CBD) para el tratamiento de tumores asociados con el Complejo de Esclerosis Tuberosa (TSC). En particular, el CBD fue capaz de reducir el número y tamaño de células marcadoras pS6 en un modelo de TSC de pez cebra. Esto es sugerente de un efecto modificador de la enfermedad por el cual el tratamiento con CBD podría resultar en la reducción o prevención de los tumores benignos que aparecen en pacientes con TSC. De preferencia, el CBD utilizado está en forma de un extracto de cannabis altamente purificado de modo que el CBD está presente en más de 98% del extracto total (p/p) y los otros componentes del extracto se caracterizan. En particular, el cannabinoide tetrahidrocannabinol (THC) se ha retirado sustancialmente a un nivel de no más de 0.15% (p/p) y el análogo de propilo de CBD, cannabidivarina, (CBDV) está presente en cantidades de hasta 1%. Alternativamente, el CBD puede ser un CBD producido de forma sintética. En uso, el CBD se da de forma simultánea con uno u otros grupos más de fármacos utilizados en el tratamiento del TSC. Tales fármacos pueden incluir rapamicina y/o everolimus.
MX2021006270A 2017-06-23 2019-12-06 Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa. MX2021006270A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1710042.1A GB2564383B (en) 2017-06-23 2017-06-23 Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex

Publications (1)

Publication Number Publication Date
MX2021006270A true MX2021006270A (es) 2021-08-11

Family

ID=59523703

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014715A MX2019014715A (es) 2017-06-23 2018-06-21 Uso de cannabidiol en el tratamiento del complejo de escleroris tuberosa.
MX2021006270A MX2021006270A (es) 2017-06-23 2019-12-06 Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019014715A MX2019014715A (es) 2017-06-23 2018-06-21 Uso de cannabidiol en el tratamiento del complejo de escleroris tuberosa.

Country Status (13)

Country Link
US (2) US20200206153A1 (es)
EP (1) EP3641819B1 (es)
JP (1) JP7383488B2 (es)
AU (1) AU2018288021B2 (es)
BR (1) BR112019027454A2 (es)
CA (1) CA3065449A1 (es)
DK (1) DK3641819T3 (es)
ES (1) ES2962890T3 (es)
FI (1) FI3641819T3 (es)
GB (1) GB2564383B (es)
IL (1) IL271492A (es)
MX (2) MX2019014715A (es)
WO (1) WO2018234811A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
GB2583526A (en) * 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB202002754D0 (en) * 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2022122904A1 (en) 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
KR20170008311A (ko) * 2014-05-29 2017-01-23 인시스 파마, 인코포레이티드 안정한 카나비노이드 제형
US20160367496A1 (en) * 2014-05-29 2016-12-22 Insys Development Company, Inc. Stable cannabinoid formulations
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
JP6899506B2 (ja) * 2015-05-28 2021-07-07 フレッシュ・カット・ディベロップメント・エル・エル・シー 安定なカンナビノイド製剤
CA3025702C (en) * 2016-05-27 2022-12-20 Insys Development Company, Inc. Stable cannabinoid formulations
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551987A (en) * 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations

Also Published As

Publication number Publication date
ES2962890T3 (es) 2024-03-21
GB2564383B (en) 2021-04-21
CA3065449A1 (en) 2018-12-27
JP2020524706A (ja) 2020-08-20
MX2019014715A (es) 2020-02-07
AU2018288021B2 (en) 2023-09-21
GB2564383A (en) 2019-01-16
EP3641819A1 (en) 2020-04-29
IL271492A (en) 2020-02-27
JP7383488B2 (ja) 2023-11-20
US20230301934A1 (en) 2023-09-28
WO2018234811A1 (en) 2018-12-27
US20200206153A1 (en) 2020-07-02
EP3641819B1 (en) 2023-10-11
DK3641819T3 (da) 2023-11-20
AU2018288021A1 (en) 2019-12-19
GB201710042D0 (en) 2017-08-09
BR112019027454A2 (pt) 2020-07-07
FI3641819T3 (fi) 2023-11-10

Similar Documents

Publication Publication Date Title
MX2021006270A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
MX2020005719A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2020005147A (es) Uso de cannabinoides en el tratamiento de convulsiones asociadas al sindrome de lennox-gastaut.
EP3687527A4 (en) COMPOSITIONS CONSISTING OF CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENES AND FLAVONOIDS AND THEIR USE IN THE TREATMENT OF INSOMNIA
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
MX2021000814A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2019001286A (es) Composicion de cannabis.
NZ726746A (en) Stable cannabinoid formulations
CR9989A (es) Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
BR112019007798A2 (pt) veículo de liberação oral
CO6382172A2 (es) Efectos antitumorales de combinaciones cannabinoides
JP2012532093A5 (es)
GB2492487A8 (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
AR100562A1 (es) Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
MX2021013285A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
WO2019074617A3 (en) Neupanex ®: neuroprotective, neuroregenerational, & neurogenesis supporting supplement combination
MX2021001333A (es) Composiciones y metodos para tratar disfuncion sexual y aumentar la respuesta y placer sexual.
CO2023000130A2 (es) Composición y método para el tratamiento del dolor crónico
WO2011093742A3 (ru) Средство для лечения болезни паркинсона